The group's principal activities are to develop engineered streptococcus mutans for oral and other therapeutic applications. The group has developed two healthcare products. The first technology product is a genetically altered strain of a species of bacteria called s mutans which occurs naturally on teeth in human beings. The second technology is an antibiotic known as mutacin 1140 effective against all tested gram-positive bacteria. Gram-positive bacteria cause many human ailments, such as pneumonia, pharyngitis and others. The group is a development stage company.
